



**HAL**  
open science

# COVID-19 mortality and health expenditures across European countries: the positive correlation puzzle

Serge Blondel, Radu Vranceanu

► **To cite this version:**

Serge Blondel, Radu Vranceanu. COVID-19 mortality and health expenditures across European countries: the positive correlation puzzle. 2020. hal-02920258v1

**HAL Id: hal-02920258**

**<https://essec.hal.science/hal-02920258v1>**

Preprint submitted on 24 Aug 2020 (v1), last revised 31 Aug 2020 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**ESSEC**  
BUSINESS SCHOOL

---

*The pioneering spirit*

# COVID-19 MORTALITY AND HEALTH EXPENDITURES ACROSS EUROPEAN COUNTRIES: THE POSITIVE CORRELATION PUZZLE

---

Serge Blondel  
Radu Vranceanu

ESSEC RESEARCH CENTER

WORKING PAPER 2005



**COVID-19 mortality and health expenditures across European countries:  
The positive correlation puzzle**

Serge Blondel, GRANEM (Angers University) and LIRAES (Paris 5 University) – 13 allée François Mitterrand, 49000 Angers, France. E-mail: [serge.blondel@univ-angers.fr](mailto:serge.blondel@univ-angers.fr)

Radu Vranceanu, ESSEC Business School and THEMA (Cergy-Pontoise University), 1 Av. Bernard Hirsch, 95000 Cergy, France. E-mail: [vranceanu@essec.edu](mailto:vranceanu@essec.edu)

**Abstract**

The positive correlation between health share expenditures and COVID-19 case fatalities in a cross-section of 31 European countries is puzzling. The positive relationship is also detected in weighted OLS and IV models that control for many usual suspects of the COVID-19 mortality: (1) health indicators (personal risk factors, medical resources), (2) virus ease of circulation, (3) macroeconomic variables related to the economic development and social orientation of the country. COVID-19 case fatalities are lower in countries with significant resources dedicated to health care (hospital beds and medical doctors); the contribution of virus circulation factors is less significant. Policy implications follow.

**KEYWORDS**


COVID-19, health care systems, Europe, efficiency, mortality, health policy

**JEL CLASSIFICATION** - H12, I18

## 1. INTRODUCTION

Europe was hit by the first wave of COVID-19 in early March 2020. As of July 25, 2020, the COVID-19 crisis had caused 20.19 deaths per 100,000 people in the EU. Except for Sweden, all countries implemented lockdown policies to reduce the contamination rate. Some countries moved very fast to closing borders; other countries had a more gradual approach. Testing and patient care policies also differed from one country to another, and sometimes from one region to another. First and foremost, countries presented quite different degrees of preparedness for such a crisis in terms of resources, organization of the health care system, and leadership. Hence, the death toll varies greatly from one country to another, from zero in Cyprus to 85 per 100,000 people in Belgium. With respect to this indicator, the most affected are the large countries in the West of Europe and Sweden (Figure 1).

**FIGURE 1** COVID-19 case fatalities per 100,000 people




The probability of dying from the COVID-19 compounds effects of two significant stages: being contaminated and symptomatically sick (stage 1) and falling into a serious condition (stage 2). Stage 1 contamination depends on the circulation of the virus, while stage 2 chances of recovery depend on the patient's own risk factors (age, obesity...) and the availability of heavy health equipment and highly-skilled medical staff.<sup>1</sup> Figure 2 illustrates the substantial differences in health expenditures across Europe.

However, how can we explain that France, which spends 11.26% of its GDP on health, recorded 45 case fatalities per 100,000 people, while Poland, with 6.52% of health spending to GDP, had 10 times less lethal cases (4.38)?

---


<sup>1</sup> Policymakers can act at the two levels, first by taking social distancing measures and then by increasing the reception capacities of hospitals.

**FIGURE 2** Health expenditures/GDP (%) in 2018 or latest year available (Eurostat)



The Polish and French comparison is not singular. Figure 3 illustrates the paradoxical positive link between the health expenditures (2018)<sup>2</sup>. and the cumulated COVID-19 deaths. The correlation coefficient is 0.51.

**FIGURE 3** Health expenditures/GDP (and cumulated COVID-19 deaths per 100,000 people).



<sup>2</sup> All our data come from Eurostat, unless otherwise indicated.

A priori, a negative link could be expected: the more resources a country dedicates to health care, the more lives should be saved during a sanitary crisis. On the other hand, the positive correlation can be driven by the relationship between another variable and each of the COVID-19 case fatalities and health expenditures. For instance, a higher proportion of old age persons is associated with both a higher share of health expenditures and a higher COVID-19 mortality. If the correlation between the health share and the death rate is still present when controlling for all other observed variables that jointly impact the two variables (age, temperatures, hospital beds, obesity, etc.), then the correlation could reveal differences in the efficiency of the health care systems, an unobserved variable. All other things being equal, the higher the efficiency of the health care system, the lower should be the health care expenses, and the lower should be the COVID19 death rate (see Online Appendix 1 for the formal explanation).<sup>3</sup>

This short paper studies whether the positive correlation between the COVID-19 death rates in Europe and the share of health care expenditures holds when controlling for the usual suspects of the COVID-19 mortality and provide a positive answer. We verify that the puzzling correlation resists to IV regressions that would correct for omitted variables and endogeneity. A lower health share coefficient in IV compared to OLS regressions suggests that the omitted variable (efficiency) hypothesis cannot be ruled out. Our analysis also reveals the factors that contributed the most to the COVID-19 first-wave mortality by country. It emphasizes the essential role of medical resources in the fight of the epidemic.

We choose to focus on European countries because the epidemy hit them at the same period (with small time differences), all have universal health care systems that cover all their citizens for all expenses related to major illnesses and would share common civic values to guide policymakers. Finally, Europe strived to address the COVID-19 epidemic in a coordinated way.

In a related paper, Khan et al. (2020) analyze the determinants of COVID-19 case fatalities across a sample of 86 developed and developing countries with different health systems. They unveil a strong negative correlation between an index of health resources and COVID-19 deaths in an OLS regression model. They also observe a positive but not significant correlation between health expenditures and the death rate. Their preferred explanation relies on the differences in the political regime, with autocracies more able to adopt harsh social distancing. This argument cannot apply to our sample.<sup>4</sup>

## **2. THE DATA**

Our sample comprises 31 countries: the 27 EU countries, the UK and the EFTA large countries (Iceland, Norway, Switzerland). With a population of 529.06 million people in 2018, they represent a large proportion of all European countries.

---

<sup>3</sup> Newhouse (2006) argues that the organization of the health care systems has an important role in determining health care expenditures.

<sup>4</sup> Many other papers in economics focus on the impact of the pandemic on the economy (see Brodeur et al., 2020 for a survey). See Chilton (2020) on the usefulness of economic research on the COVID-19.

The first variable of interest is the COVID-19 total deaths per 100,000 people (or death rate) from the beginning of the epidemic until July 25, 2020.<sup>5</sup> This date can be reasonably be seen as the end of the first wave. Indeed, compared to the late April peak in the 14-day COVID-19 death notification rate, totaling 105 people per 1,000,000 population for the EU/EEA and the UK, on August 2, 2020, the same indicator was as low as 4.1 (ECPDC, 2020). The rate has been stable for 13 days.

The second variable of interest is the share of health expenditures to GDP (in percentage points) (Figure 2). The Eurostat data are available for 2018 (thus the COVID-19 extra spending is not included).

The analysis considers several explanatory variables, grouped in three categories.

**I. Health indicators.** Within the health care system, human resources (medical doctors and nurses) and hospital beds (ICU mainly) were key resources in fighting the COVID-19. Both human and material resources were stretched at the peak of the crisis, with large differences from one country to another. Old age and overweight were pointed out as major factors of risk (inter alia, Al Saidi et al., 2020; Beeching et al. 2020, ECDPC 2020); they also contribute to higher health expenses as they are associated to many critical diseases, such as cancer or heart fragility.

**II. Virus circulation.** Temperature might influence the spread of COVID-19. Population density could also have played a role. The less a country allows for travel and exchange with the rest of the world in the first stages of the epidemic, the lower the speed of contamination. As a proxy for openness, we use the share of exports in GDP.

**III. Macroeconomic variables.** Public debt to GDP is a proxy for the strain imposed on governments in taking decisive action against the COVID-19. The Gini inequality index is also a proxy for the social orientation of the institutions.<sup>6</sup>

As auxiliary variables, that are useful for the regression analysis, we present the country population and its real GDP per capita or Affluence.

---

<sup>5</sup> COVID-19 case fatalities is a noisy measure, since not all deaths are correctly imputed due to test shortages and false negative tests, and some deaths determined by other main causes might be wrongly attributed to COVID-19.

<sup>6</sup> Kennedy et al. (1998) find that higher Gini coefficients across US states were associated with lower levels of overall health.

**TABLE 1** Summary statistics of the data over 31 countries<sup>7</sup>

	Mean	SD	Min	Max
Key variables				
- COVID deaths per 100,000 people	19.22	23.66	0	85
- Health expenditures / GDP, in % (2018)	8.4	1.89	5.29	12.35
Health related indicators				
- Obesity rate (BMI>30) in % (2016)	22.79	2.51	19.5	28.8
- Rate of aged 80 and more in % (2017)	4.86	0.96	3.2	6.8
- Rate of aged 65-79 in % (2017)	18.37	2.33	13.9	22.3
- Median age (2017)	41.59	2.37	36.3	46.8
- Hospital beds per 10,000 people (2017)	481.67	169.1	221.2	800.2
- Medical doctors per 10,000 people (2016)	35.62	8.26	19.50	54.04
Circulation of the virus				
- Exportations / GDP, in % (2019)	66.88	37.2	31.6	208.8
- Mean temperature (°C)(1961-1990)	8.83	4.45	1.5	19.2
- Geographic density (population per Km <sup>2</sup> )	172.14	288.31	3.54	1628.37
Macroeconomic variables				
- Real GDP/capita (€) or Affluence (2019)	30,561	18,893	6,800	83,640
- Public debt / GDP, in % (2019)	61.9	36.72	8.4	176.6
- Gini index (2017)	31.2	3.95	24.2	40.4
- Population in millions (2018)	17.07	23.03	0.36	83.17

Source: Eurostat, except rate of obesity (WHO, 2016), the medical doctors per 10,000 people (WHO, 2016, except for Bulgaria and Malta, 2015) the number of COVID deaths (Worldometers), the mean temperature (Climate Research Unit, University of East Anglia), and the Gini coefficient (World Bank).

### 3. THE ECONOMETRIC ANALYSIS

The COVID-19 case fatality rate can be interpreted as the probability of death, from the beginning of the pandemic to the 25<sup>th</sup> of July, for an individual living in a given country. As other death probability models, a model based on variables measuring country averages builds on an underlying individual death probability model. It is therefore meaningful to implement weighted regressions, using the population share as a weight for each country (Wooldridge, 2006).<sup>8</sup>

One element of interest is the relationship between the health share expenditures and the COVID-19 fatalities. As we argued before, the coefficients in OLS regressions can be biased, due to endogeneity problems (for instance, old age is determining both health expenses and is a COVID-19 risk factor), and omitted variable (the unobserved efficiency of the health system).

To correct for these potential problems, we also implement a set of IV regressions. Real GDP/capita (or Affluence) is a natural candidate to be the instrument, since it is correlated with the health share but not with the COVID-19 death rate. Why, in our sample, affluence would not be correlated with the death rate? Because all of the 31 countries run universal health care systems that cover all expenses related to the major illnesses. The treatment of COVID-19 did not require expensive drugs, only a dedicated medical staff

<sup>7</sup> The correlation matrix is presented in the Online Appendix.

<sup>8</sup> The results of the unweighted regressions do not differ much. See Online Appendix 4.

and ICU hospital beds for the most difficult cases.<sup>9</sup> On the other hand, the affluence should be positively correlated with the share of health care expenditures at country level, for many reasons. In a Belassa-Samuelson framework, richer countries have higher wages, and a higher productivity in the production of tradable goods. Because health care is a non-tradable good and countries should feature a similar productivity, richer countries should have higher health shares. Other explanations were provided to this documented correlation (Hall and Jones, 2007). Getzen (2000) suggests that health care services are a necessity good at the individual level (income elasticity lower than 1) and a luxury good at the country level.

**TABLE 2** COVID-19 fatality rate: OLS and IV regressions, weighted by the population

	Weighted OLS			Weighted IV		
	Model 1	Model 2	Model 3	Model 1	Model 2	Model 3
Health Expend./GDP	4.267*** (1.14)	5.406*** (1.24)	6.368*** (1.40)	3.905** (1.54)	4.288*** (1.53)	4.705** (1.83)
Obesity rate	1.436* (0.77)	1.630* (0.89)	1.217 (1.08)	1.433** (0.68)	1.609** (0.73)	1.369 (0.86)
Age (% above 80)	13.540*** (2.88)	16.418** (6.53)	12.727 (9.81)	13.801*** (2.71)	17.222*** (5.82)	15.101* (8.54)
Hospital beds/10,000	-0.079*** (0.01)	-0.081*** (0.01)	-0.077*** (0.02)	-0.079*** (0.01)	-0.080*** (0.01)	-0.077*** (0.01)
Medical doctors /10,000	-1.623*** (0.42)	-2.027*** (0.65)	-2.018*** (0.71)	-1.612*** (0.39)	-1.951*** (0.54)	-1.934*** (0.57)
Mean temperature		1.044 (0.72)	1.105 (1.08)		0.738 (0.72)	0.723 (0.95)
Density		0.004 (0.02)	-0.000 (0.02)		0.011 (0.02)	0.010 (0.02)
Exports / GDP		0.289 (0.25)	0.330 (0.25)		0.266 (0.20)	0.286 (0.19)
Public debt / GDP			0.050 (0.17)			0.033 (0.14)
Gini index			1.005 (1.07)			0.576 (0.97)
Constant	-14.634 (30.10)	-54.521 (46.44)	-74.720* (42.07)	-13.167 (26.37)	-48.378 (37.49)	-59.025* (35.59)
R <sup>2</sup>	0.804	0.840	0.846	0.803	0.837	0.841
N	31	31	31	31	31	31

Legend: \* Significant at 10%. \*\* Significant at 5%. \*\*\* Significant at 1%. Standard errors between brackets.

The correlation between the health share and the COVID-19 death rate holds even if controlling for all these “usual suspects”. The coefficient of the health share expenditure in the IV regressions is lower compared to the OLS regressions, suggesting that differences in the efficiency of the health system could be an explanation. However, the coefficient is still positive and statistically significant, revealing a persistent puzzle. It is possible that our instrument is not powerful enough, albeit the Shea’s partial R<sup>2</sup> (higher than 0.60) and the p-val>F (close to zero) suggest that it is (see last lines of Table 3).

Medical resources appear to be very powerful determinants of the success in the fight against the epidemic. Old age also appears to be important, which is in line with the standard facts known about the COVID-19 mortality. On the contrary, macroeconomic variables and variables related to the circulation of the virus are not significant. This

<sup>9</sup> As a caveat, richer people could be in a better health (Semyonov et al 2013), thus could be more resistant to the COVID-19.

might call for a thorough policy evaluation of the social distancing measures as implemented by all of these countries (with the notable exception of Sweden).

**TABLE 3** The health share equation: First equation in the 2SLS IV regressions (population weights)

	Model 1 IV	Model 2 IV	Model 3 IV
Obesity rate	0.111 (0.080)	0.037 (0.084)	0.093 (0.074)
Age (% above 80)	0.962*** (0.272)	0.367 (0.304)	0.825** (0.299)
Hospital beds/10,000	0.003*** (0.0008)	0.003** (0.001)	0.002* (0.001)
Medical doctors/10,000	-0.015 (0.031)	0.024 (0.010)	0.018 (0.037)
Mean temperature		-0.013 (0.073)	-0.012 (0.070)
Density		0.003 (0.002)	0.003* (0.001)
Exports to GDP		-0.030** (0.013)	-0.032*** (0.009)
Debt to GDP			-0.007 (0.007)
Gini index			-0.145* (0.007)
Affluence	0.122*** (0.018)	0.113*** (0.028)	0.101*** (0.025)
Constant	-2.916 (2.372)	1.813 (3.368)	4.392 (3.059)
N	31	31	31
R2	0.787	0.837	0.867
Shea's Partial R2	0.727	0.636	0.615
Proba > F	0.0000	0.0005	0.0006

Legend: \* Significant at 10%. \*\* Significant at 5%. \*\*\* Significant at 1%. Standard errors between brackets.

In line with the above-mentioned papers and theory, affluence is strongly correlated with the health share (which justifies its use as an instrument). The Gini index is negatively associated (more egalitarian countries spending relatively more on health care).

As expected, old age (a pull factor) and hospital beds/1,000 people (a push factor) are both associated with higher health shares in a given country. However, the number of doctors per 10,000 population is not associated to higher share of health expenditures.

#### 4. DISCUSSION

We document a positive correlation between the share of health expenditures in the GDP prior to the epidemic and the death rates during the first wave, as it appears in a cross-section of 31 European countries.

We show that the correlation is robust to including the usual suspects in the case fatality regression model. The comparison of the health share coefficient between OLS and IV

models suggest that unobserved variables, such as the efficiency of the health care system, can be at work. However, the “puzzle” is still present in IV models that strive to control for such a bias. This might be related to the quality of our instrumental variable, although theory and empirical tests suggest it is a satisfactory choice. Another explanation, difficult to verify, would involve possible heterogeneity in the reporting of the COVID case fatalities.

The COVID-19 death rate equation points out to the essential role played by the medical resources in taming COVID mortality, compared to personal risk and virus circulation factors. In the light of this result, to prepare for a would-be second wave, governments might strive to invest in emergency measures to strengthen their hospitals, rather than to impose new lockdowns, which are less efficient and much more harmful for the economy.

In the long run, countries should aim to improve the efficiency of the health care systems, by allowing for additional flexibility following for instance the example of Germany. One should not neglect the lasting economic consequences of the lack of medical preparedness.<sup>10</sup> The EU could help, by developing a common strategy, following the example of the countries which have had the best results in managing both the epidemic and the economic crisis.

## REFERENCES

- Brodeur, A., Gray, D., Islam, A., & Jabeen Bhuiyan S. (2020). A literature review of the economics of COVID-19. *IZA Discussion Paper* No. 13411
- Beeching N., Fletcher T. & Fowler E. (2020). Coronavirus disease 2019 (COVID-19), *A BMJ Report updated on 13 August 2020*, <https://bestpractice.bmj.com/topics/en-gb/3000168/pdf/3000168/Coronavirus%20disease%202019%20%28COVID-19%29.pdf>
- Chilton, S., Nielsen, J. S., & Wildman J. (2020). Beyond COVID-19: How the ‘dismal science’ can prepare us for the future. *Health Economics*, 29, 851–853.
- ECDC (2020), Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – eleventh update: resurgence of cases, European Center of Disease Prevention and Control, August 2020, <https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-20200810.pdf>
- Eurostat (2020). News release, euro indicators, 121/2020, 31 July.
- Gibney E. (2020) Whose coronavirus strategy worked best? Scientists hunt most effective policies. *Nature*, 581, 15–16.
- Getzen, T. E. (2000). Health care is an individual necessity and a national luxury: applying multilevel decision models to the analysis of health care expenditures. *Journal of Health Economics*, 19, 259–270
- Hall, Robert E., & Charles I. Jones. (2007) The value of life and the rise in health spending, *Quarterly Journal of Economics* 122.1: 39-72.

---

<sup>10</sup> As an example, in the first two quarters of 2020, the GDP fell by 2% and 10.1% in Germany, compared to 5.9% and 13.8% in France (Eurostat, 2020).

- Kennedy, B. P., Kawachi, I., Glass, R., & Prothrow-Stith, D. (1998). Income distribution, socioeconomic status, and self-rated health: a U.S. multi-level analysis. *British Medical Journal*, 317 (7163), 917e921.
- Khan, J. R., Awan, N., Islam, M., & Muurlink, O. (2020). Healthcare capacity, health expenditure, and civil society as predictors of COVID-19 case fatalities: A global analysis, *Frontiers in Public Health*, 8, 347.
- Newhouse, J. P. (2006). Commentary on Getzen's "Aggregation and the measurement of health care costs", *Health Research and Educational Trust*. doi:10.1111/j.1475-6773.2006.00559.x
- Obaid Al Saidi, A. M., Nur, F. A., Al-Mandhari, A. S., El Rabbat, M., Hafeez, A., & Abubakar, A. (2020). Decisive leadership is a necessity in the COVID-19 response. *The Lancet*, 396 , 295-298.
- Semyonov, Moshe, Noah Lewin-Epstein, & Dina Maskileyson. (2013): Where wealth matters more for health: The wealth–health gradient in 16 countries, *Social Science & Medicine* 81 10-17.
- Wooldridge, J. M. (2006). *Introductory Econometrics: A Modern Approach*. 2<sup>nd</sup> Edition, South Western.

## ONLINE APPENDIX.

### APPENDIX 1 The efficiency channel

In a very simple way, the health expenditures  $H$  can be written as a function of variables related to the demand (pull) and supply (push) for health services, themselves related to the personal characteristics of the population, and public choices about how many resources to dedicate to the health sector:

$$H = AX - v, \quad (1)$$

where  $X$  is the vector of relevant variables and  $A$  is the vector of coefficients.  $v$  is an unobserved variable, that captures the efficiency of the medical system. A larger  $v$  requires less health expenditures for the same service.

Then, denoting by  $Y$  the mortality factors specific to the COVID-19 other than those included in  $X$ , such as the temperature or the degree of country openness, the COVID-19 death rate  $D$  is given by :

$$D = BX + GY - \mu v \quad (2)$$

In this expression, the coefficient  $\mu > 0$  captures the effect of the general efficiency of the health care system on the efficiency of treating COVID-19 cases. Replacing  $v$  as implicitly defined by the former equation in the second, we obtain:

$$D = (B - \mu A)X + GY + \mu H \quad (3)$$

When the efficiency factor is brought into the picture, death rates ( $D$ ) and health expenditures ( $H$ ) exhibit a positive correlation. The coefficients of variables in the set  $X$  are subject to offsetting forces, since both vectors  $B$  and  $A$  contain positive scalars.

### APPENDIX 2. The correlation matrix

	DEATHR~O	HLTHEX~P	OBE~2016	A~802017	A~652017	AGEDMED	BEDS2017
DEATHRATIO	1.0000						
HLTHEXTOGDP	0.4428	1.0000					
OBESITY2016	-0.0739	-0.3510	1.0000				
AGABO~802017	0.3615	0.3437	-0.1214	1.0000			
AGEAB~652017	0.1175	0.2043	0.0455	0.8046	1.0000		
AGEDMED	0.0139	0.2480	-0.0809	0.7470	0.8331	1.0000	
BEDS2017	-0.3749	-0.2459	0.1894	-0.0009	0.1362	0.3408	1.0000
MED10000	-0.0543	0.3209	-0.1363	0.5120	0.4873	0.5061	0.0243
MEANTEMP	0.0808	-0.1128	0.4462	0.2402	0.3632	0.2538	0.1444
DENSITY	0.0584	0.1959	0.3856	-0.1042	0.0414	0.0564	-0.0344
EXPTOGDP	-0.1447	-0.3660	0.2158	-0.5060	-0.4500	-0.2868	0.0661
DEBTTOGDP	0.3471	0.1894	-0.0073	0.5839	0.3743	0.2168	-0.2020
GINI	0.1283	-0.2466	0.2908	0.3788	0.2931	0.1728	0.1389
AFFLUENCE	0.2595	0.4053	-0.3160	-0.2247	-0.5042	-0.3295	-0.4291
POPMIL	0.5009	0.3783	0.0223	0.4840	0.3187	0.3408	0.0887
	MED10000	MEANTEMP	DENSITY	EXPTOGDP	DEBTTO~P	GINI	AFFLUE~E
MED10000	1.0000						
MEANTEMP	0.1253	1.0000					
DENSITY	-0.1776	0.4997	1.0000				
EXPTOGDP	-0.2427	0.1633	0.4274	1.0000			
DEBTTOGDP	0.2649	0.4299	-0.0268	-0.3703	1.0000		
GINI	0.1541	0.1805	-0.0987	-0.0534	0.1581	1.0000	
AFFLUENCE	-0.0283	-0.3555	0.0116	0.3549	-0.1603	-0.1617	1.0000
POPMIL	-0.0098	0.1870	-0.0016	-0.4266	0.3621	0.2461	-0.0395

**APPENDIX 3.** The list of countries and the symbol (United Nations) used in the text

Country	Symbol (UN)
Austria	AUT
Belgium	BEL
Bulgaria	BGR
Croatia	HRV
Cyprus	CYP
Czech Republic	CZE
Denmark	DNK
Estonia	EST
Finland	FIN
France	FRA
Germany	DEU
Greece	GRC
Hungary	HUN
Ireland	IRL
Italy	ITA
Latvia	LVA
Lithuania	LIT
Luxembourg	LUX
Malta	MLT
Netherlands	NLD
Poland	POL
Portugal	PRT
Romania	ROU
Slovak Republic	SVK
Slovenia	SVN
Spain	ESP
Sweden	SWE
United Kingdom	GBR
Iceland	ISL
Norway	NOR
Switzerland	CHE

## APPENDIX 4. Unweighted OLS regression

	OLS1	OLS2	OLS3	IV1	IV2	I3
HLTHEXTOGDP	4.784** (2.18)	8.926*** (2.78)	9.419*** (2.93)	9.213* (5.11)	7.405** (3.21)	7.188** (3.14)
OBESITY2016	1.111 (1.51)	2.161 (1.75)	1.671 (1.88)	1.989 (1.73)	1.776 (1.58)	1.227 (1.59)
AGABO-802017	10.750** (4.36)	12.301** (4.94)	9.223 (6.15)	8.824* (4.68)	12.525*** (4.20)	9.892* (5.05)
BEDS2017	-0.041* (0.02)	-0.043* (0.02)	-0.041* (0.02)	-0.031 (0.02)	-0.045** (0.02)	-0.043** (0.02)
MED10000	-1.083** (0.51)	-1.509*** (0.52)	-1.495** (0.54)	-1.263** (0.53)	-1.406*** (0.46)	-1.347*** (0.46)
MEANTEMP		1.274 (1.08)	1.184 (1.27)		1.087 (0.95)	0.851 (1.07)
DENSITY		-0.042* (0.02)	-0.039* (0.02)		-0.035* (0.02)	-0.029 (0.02)
EXPTOGDP		0.249* (0.13)	0.241* (0.14)		0.215* (0.12)	0.197 (0.12)
DEBITOGDP			0.048 (0.14)			0.083 (0.11)
GINI			0.982 (1.11)			0.805 (0.92)
_cons	-40.205 (46.19)	-111.108* (58.43)	-123.265* (61.50)	-86.457 (66.09)	-90.848 (57.37)	-92.880 (57.36)
r2	0.450	0.557	0.575	0.358	0.551	0.563
N	31	31	31	31	31	31

**ESSEC Business School**

3 avenue Bernard-Hirsch  
CS 50105 Cergy  
95021 Cergy-Pontoise Cedex  
France  
Tel. +33 (0)1 34 43 30 00  
[www.essec.edu](http://www.essec.edu)

**ESSEC Executive Education**

CNIT BP 230  
92053 Paris-La Défense  
France  
Tel. +33 (0)1 46 92 49 00  
[www.executive-education.essec.edu](http://www.executive-education.essec.edu)

**ESSEC Asia-Pacific**

5 Nepal Park  
Singapore 139408  
Tel. +65 6884 9780  
[www.essec.edu/asia](http://www.essec.edu/asia)

ESSEC | CPE Registration number 200511927D  
Period of registration: 30 June 2017 - 29 June 2023  
Committee of Private Education (CPE) is part of SkillsFuture Singapore (SSG)

**ESSEC Africa**

Plage des Nations - Golf City  
Route de Kénitra - Sidi Bouknadel (Rabat-Salé)  
Morocco  
Tel. +212 (0)5 37 82 40 00  
[www.essec.edu](http://www.essec.edu)

**CONTACT:**

**RESEARCH CENTER**

[research@essec.edu](mailto:research@essec.edu)